Editas Medicine (EDIT) investor relations material

Executive summary

• EDIT-401, an in vivo gene editing therapy for hyperlipidemia and HeFH, is the lead candidate, showing >90% mean LDL-C reduction in preclinical studies and significant reductions in Lp(a) and ApoB in non-human primates; first-in-human trials are planned for 2026 with topline data expected in 2027.

• The company shifted resources to EDIT-401 after discontinuing the reni-cel program for sickle cell disease and beta thalassemia, resulting in a major workforce reduction and restructuring.

• Revenue is primarily from collaboration and license agreements, with no product sales to date.

• U.S. Patent and Trademark Office reaffirmed Broad Institute's CRISPR/Cas9 patent rights, favoring Editas' exclusive license.

Financial highlights

• Net loss for Q1 2026 was $25.0M ($0.26 per share), a significant improvement from $76.1M ($0.92 per share) in Q1 2025.

• Collaboration and other R&D revenues were $2.8M for Q1 2026, down 39% year-over-year, mainly due to the conclusion of a collaboration agreement.

• Operating expenses decreased 66% year-over-year to $27.8M, reflecting lower R&D and G&A costs and absence of restructuring charges.

• Cash and cash equivalents totaled $123.6M as of March 31, 2026, down from $146.6M at year-end 2025.

• Accumulated deficit reached $1.7B as of March 31, 2026.

Outlook and guidance

• Existing cash and cash equivalents expected to fund operations into Q3 2027.

• Plans to complete enrollment of the dose-finding portion of the EDIT-401 clinical trial with topline data in 2027.

• Expenses projected to remain consistent as resources focus on advancing EDIT-401 and preclinical pipeline.

• No profitability expected for 2026 or the foreseeable future.

• Multiple upcoming scientific and investor presentations scheduled for 2026.